A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer
A Study to Evaluate Safety in Participants with Chemotherapy-naïve Stage IV or Recurrent Non-small Cell Lung Cancer Treated With Nivolumab in Combination with Ipilimumab
Non-Small Cell Lung Cancer
DRUG: Nivolumab|DRUG: Ipilimumab
Incidence of high grade (Grade 3-4 and Grade 5) treatment-related select adverse events, Approximately 3 months|Incidence of high grade (Grade 3-4 and Grade 5) immune-mediated adverse events, Approximately 3 months
Progression-free survival (PFS) as determined by the investigator using Response Evaluation Criteria in Solid Tumors (RECIST v1.1), Up to 24 months|Objective Response Rate (ORR) as assessed by the Investigator using tumor progression per Response Evaluation Criteria in Solid Tumors (RECIST v1.1), Up to 24 months|Overall survival (OS) as defined as the time from first dosing to the date of death, Up to 5 years|Duration of Response (DOR) as assessed by the investigator using Response Evaluation Criteria in Solid Tumors (RECIST v1.1), Up to 24 months
A Study to Evaluate Safety in Participants with Chemotherapy-naïve Stage IV or Recurrent Non-small Cell Lung Cancer Treated With Nivolumab in Combination with Ipilimumab